NewsEvents

Your Yourlocation: Home > The TONADO ™ study showed that tiotropium bromide(136310-93-5) plus valodatolide FDC can provide significant improvements in lung function

The TONADO ™ study showed that tiotropium bromide(136310-93-5) plus valodatolide FDC can provide significant improvements in lung function and health-related quality of life beyond the two drug monotherapy. These data highlight the potential of tiotropium bromide plus dortacol® FDC as a quick-acting, long-acting, daily administration of chronic obstructive pulmonary care therapy options.

"The results of the TONADO ™ study have brought more hope for patients with chronic obstructive pulmonary disease," continued Professor Rabe. "For example, the improvement in the quality of life score shown by the institute can help patients to more easily engage in daily activities such as washing, dressing, shopping, and stairs."

The data also show that tiotropium bromide(136310-93-5) plus dartrazone has a good tolerance and safety comparable to that of tiotropium or odatrox monotherapy. The TONADO ™ study and the results of the VIVACITO ™ study published earlier this year constitute an important component of the recently filed application materials for the treatment of triclosan in the presence of tiotropium in combination with tiotropium plus lidocaine section.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved